Results 21 to 30 of about 1,745 (114)

Diagnostic accuracy and clinical value of [68Ga]Ga-FAPI-46 PET/CT for staging patients with ovarian cancer: study protocol for a prospective clinical trial. [PDF]

BMC Cancer
Background [18F]Fluorodeoxyglucose ([18F]FDG) positron emission tomography (PET) is recommended during diagnostic work-up for ovarian cancer; however, [18F]FDG PET has several inherent limitations.
Bentestuen M, Ladekarl M, Knudsen A, Zacho HD.   +3 more
europepmc   +2 more sources

A 3D co-culture model with fibroblast-restricted FAP expression for cancer therapy using [²¹²Pb]Pb-FAPI-46. [PDF]

EJNMMI Radiopharm Chem
Background Targeting components of the tumor microenvironment has become a pan-cancer treatment strategy. Fibroblast activation protein (FAP)-targeted radioligand therapy exploits FAP expression in cancer-associated fibroblasts (CAFs) within the tumor ...
Kristiansen SK, Dernjani N, Bruland ØS, Edin NFJ, Juzeniene A.   +4 more
europepmc   +2 more sources

Image analysis: ⁶⁸Ga-FAPI-46 PET derived texture parameters improve the differentiation of malignant and benign pulmonary lesions. [PDF]

Cancer Imaging
Background Pulmonary lesions inconclusive in 18F-FDG PET/CT are a known clinical problem. Both texture analysis and 68Ga-FAPI-46 have shown potential in thoracic oncological problems but their combination has not been assessed yet.
Wessendorf J, Spektor AM, Aboulmaouahib B, Daum J, Glatting FM, Schlamp K, Grott M, Eichhorn F, Heußel CP, Kauczor HU, Kreuter M, Schreckenberger M, Winter H, Haberkorn U, Röhrich M.   +14 more
europepmc   +2 more sources

Preclinical evaluation of [⁶⁸Ga]Ga-AAZTA-FAPI-46: a novel PET tracer for targeting fibroblast activation protein (FAP). [PDF]

EJNMMI Radiopharm Chem
Background The aim of this work was to demonstrate the suitability of AAZTA chelator conjugated to a FAPI-46-derived FAP inhibitor and labelled with gallium-68 as a potential PET tracer.
Rizzo R, Rainone P, Stefania R, Belloli S, Valtorta S, Coliva A, Maspero M, Avalle L, Capozza M, Moresco RM, D'Alessandria C, Terreno E.   +11 more
europepmc   +2 more sources

Safety of [⁶⁸Ga]Ga-FAPI-46 PET/CT including hemodynamic measurements and patient-reported outcomes in cancer patients. [PDF]

Clin Physiol Funct Imaging
Abstract Introduction Aim Fibroblast activation protein inhibitor (FAPI) has demonstrated promising oncological diagnostic performance. Although no adverse events (AEs) have been previously reported, a formal safety evaluation of FAPI PET/CT is lacking.
Bentestuen M, Sylvest C, Jensen SB, Soro LR, Knudsen A, Ladekarl M, Thorlacius-Ussing O, Fendler WP, Zacho HD.   +8 more
europepmc   +2 more sources

Automated synthesis of [68Ga]Ga-FAPI-46 without pre-purification of the generator eluate on three common synthesis modules and two generator types

EJNMMI Radiopharmacy and Chemistry, 2022
Background The recent development of quinoline-based radiotracers, which act as fibroblast activation protein inhibitors (FAPIs), has shown promising preclinical and clinical advantages.
Ammar Alfteimi, Ulf Lützen, Alexander Helm, Michael Jüptner, Marlies Marx, Yi Zhao, Maaz Zuhayra   +6 more
doaj   +1 more source

New Fully Automated Preparation of High Apparent Molar Activity ⁶⁸Ga-FAPI-46 on a Trasis AiO Platform

Molecules, 2022
A large number of applications for fibroblast activation protein inhibitors (FAPI)-based PET agents have been evaluated in conditions ranging from cancer to non-malignant diseases such as myocardial infarction. In particular, 68Ga-FAPI-46 was reported to
Chiara Da Pieve, Marta Costa Braga, David R. Turton, Frank A. Valla, Pinar Cakmak, Karl-Heinz Plate, Gabriela Kramer-Marek   +6 more
doaj   +1 more source

Fully-automated production of [68Ga]Ga-FAPI-46 for clinical application

EJNMMI Radiopharmacy and Chemistry, 2020
Background [68Ga]Ga-FAPI-46 is a promising radiopharmaceutical for in vivo detection of the fibroblast activation protein by positron emission tomography. Until now, the synthesis of [68Ga]Ga-FAPI-46 has been only performed manually.
Sarah Spreckelmeyer, Matthias Balzer, Simon Poetzsch, Winfried Brenner   +3 more
doaj   +1 more source

Gallium-68-labeled fibroblast activation protein inhibitor-46 PET in patients with resectable or borderline resectable pancreatic ductal adenocarcinoma: A phase 2, multicenter, single arm, open label non-randomized study protocol.

PLoS ONE, 2023
BackgroundPancreatic ductal adenocarcinoma (PDAC) is a lethal disease prone to widespread metastatic dissemination and characterized by a desmoplastic stroma that contributes to poor outcomes.
Aashna Karbhari, Sherly Mosessian, Kamaxi H Trivedi, Frank Valla, Mark Jacobson, Mark J Truty, Nandakumar G Patnam, Diane M Simeone, Elcin Zan, Tracy Brennan, Hongli Chen, Phillip H Kuo, Ken Herrmann, Ajit H Goenka   +13 more
doaj   +1 more source

Fully-automated synthesis of 177Lu labelled FAPI derivatives on the module modular lab-Eazy

EJNMMI Radiopharmacy and Chemistry, 2021
Background To the best of our knowledge, manually production of [177Lu]Lu-FAPI radiopharmaceutical derivatives has been only described in literature. In this work, a fully-automated [177Lu]Lu-FAPI synthesis has been well designed for the first time using
Kurtulus Eryilmaz, Benan Kilbas
doaj   +1 more source